On Friday, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was 2.44% up from the session before settling in for the closing price of $7.39. A 52-week range for BCRX has been $4.03 – $8.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 190.00% over the last five years. When this article was written, the company’s average yearly earnings per share was at 68.26%. With a float of $189.08 million, this company’s outstanding shares have now reached $207.12 million.
The firm has a total of 536 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.91%, operating margin of -9.84%, and the pretax margin is -30.09%.
Biocryst Pharmaceuticals Inc (BCRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Biocryst Pharmaceuticals Inc stocks. The insider ownership of Biocryst Pharmaceuticals Inc is 8.71%, while institutional ownership is 78.73%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,780. In this transaction Director of this company sold 7,000 shares at a rate of $7.54, taking the stock ownership to the 86,638 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director proposed sale 7,000 for $7.51, making the entire transaction worth $52,584.
Biocryst Pharmaceuticals Inc (BCRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 68.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
You can see what Biocryst Pharmaceuticals Inc (BCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Analysing the last 5-days average volume posted by the [Biocryst Pharmaceuticals Inc, BCRX], we can find that recorded value of 2.72 million was lower than the volume posted last year of 2.85 million. As of the previous 9 days, the stock’s Stochastic %D was 29.06%. Additionally, its Average True Range was 0.36.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 45.19%, which indicates a significant increase from 43.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.42% in the past 14 days, which was lower than the 50.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.62, while its 200-day Moving Average is $6.76. Now, the first resistance to watch is $7.70. This is followed by the second major resistance level at $7.82. The third major resistance level sits at $8.05. If the price goes on to break the first support level at $7.35, it is likely to go to the next support level at $7.12. Should the price break the second support level, the third support level stands at $7.00.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
There are 207,133K outstanding shares of the company, which has a market capitalization of 1.61 billion. As of now, sales total 331,410 K while income totals -226,540 K. Its latest quarter income was 117,090 K while its last quarter net income were -14,030 K.
